1,2-diisopropyl-pyrazolidine | 38704-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1,2-diisopropyl-pyrazolidine
• 英文别名: 1,2-Diisopropylpyrazolidin；Pyrazolidine, 1,2-bis(1-methylethyl)-；1,2-di(propan-2-yl)pyrazolidine
• CAS: 38704-87-9
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: JRBKSHVMLIBBBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2-二(丙-2-基)肼 在 甲醇 、 lithium aluminium tetrahydride 、 sodium methylate 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 1,2-diisopropyl-pyrazolidine
  参考文献：
  名称：

  Usachev, Sergey V.; Nikiforov, Grygorii A.; Strelenko, Yurii A., Mendeleev Communications, 2002, vol. 12, # 5, p. 189 - 193

  摘要：

  DOI：

文献信息

• PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY
  申请人：Hattori Kazunari

  公开号：US20130096109A1

  公开（公告）日：2013-04-18

  An object of the present invention is to provide a novel integrase inhibitor. The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.

  本发明的一个目的是提供一种新型整合酶抑制剂。本发明涉及一种具有抗病毒作用的新型化合物，更具体地说，一种具有HIV整合酶抑制活性的吡啶酮衍生物，以及含有该化合物的药物，特别是一种抗HIV剂。本发明的化合物具有整合酶抑制活性和/或对病毒，特别是HIV及其耐药菌株的细胞增殖抑制活性。因此，该化合物在预防或治疗各种疾病、病毒感染（例如艾滋病）等方面是有用的，这些疾病中整合酶参与其中。
• Chemokine receptor modulators
  申请人：Clark Michael P.

  公开号：US20080293711A1

  公开（公告）日：2008-11-27

  The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I). These compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.

  本发明提供了化合物(I)及包含化合物(I)的药物组合物。这些化合物可用于治疗或预防HIV感染，并用于治疗增殖性疾病，如抑制各种癌症的转移。
• ANTIVIRAL COMPOUNDS
  申请人：Guo Hongyan

  公开号：US20120157404A1

  公开（公告）日：2012-06-21

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
  申请人：YOSHIDA Hiroshi

  公开号：US20120208998A1

  公开（公告）日：2012-08-16

  A compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent, of the formula: wherein R 1 , R 2 , R 3 , R 4 , B 1 and B 2 are defined in the specification.

  一种具有抗病毒活性，特别是HIV整合酶抑制活性的化合物，以及公式为：其中R1、R2、R3、R4、B1和B2在说明书中定义的制药组合物，特别是抗HIV制剂。
• Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity
  申请人：Yoshida Hiroshi

  公开号：US20090143356A1

  公开（公告）日：2009-06-04

  Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R 1 is hydrogen or lower alkyl; X is lower alkylene etc.; R 2 is optionally substituted aryl; R 3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R 4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B 1 and B 2 are such that any one of them is CR 20 R 21 , and the other is NR 22 and, in this case, there is no broken line. When B 2 is NR 22 , R 4 and R 22 may be connected together to form an optionally substituted heterocycle; When B 2 is CHR 21 , R 4 and R 21 may be connected together to form an optionally substituted heterocycle. Alternatively, B 1 and B 2 are independently C, CR 23 or N and, in this case, B 1 and B 2 may be taken together to form a heterocycle. R 20 , R 21 , R 22 and R 23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)

  提供具有抗病毒活性的新化合物，特别是具有HIV整合酶抑制活性的化合物，并提供一种药物组合物，特别是一种抗HIV剂。(其中，R1为氢或低碳基；X为低碳基亚烷等；R2为可选取代芳基；R3为氢、卤素、羟基、可选取代低碳基等；R4为氢、可选取代低碳基、可选取代环烷基、可选取代环烷基低碳基、可选取代芳基、可选取代芳基低碳基、可选取代杂环基、可选取代杂环低碳基等；断线表示键的存在或不存在；B1和B2是这样的，其中任何一个是CR20R21，另一个是NR22，此时没有断线。当B2为NR22时，R4和R22可以连接在一起形成可选取代的杂环；当B2为CHR21时，R4和R21可以连接在一起形成可选取代的杂环。或者，B1和B2分别是C、CR23或N，此时B1和B2可以连接在一起形成杂环。R20、R21、R22和R23分别为氢、可选取代低碳基、可选取代环烷基、可选取代环烷基低碳基等。